Literature DB >> 31901905

Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimer's Disease Subjects: Evidence for Disease Heterogeneity.

Meredith L Phillips1, Eddie C Stage2,3, Kathleen A Lane3,4, Sujuan Gao3,4, Shannon L Risacher3,5, Naira Goukasian6, Andrew J Saykin3,5,7,8, Maria C Carrillo9, Bradford C Dickerson10, Gil D Rabinovici11, Liana G Apostolova2,3,5,7,8.   

Abstract

BACKGROUND/AIMS: Alzheimer's disease (AD) with onset before 65 (early-onset AD [EOAD]) occurs in approximately 6% of cases and can affect nonmemory domains. Here, we analyze patterns of impairment in amnestic EOAD individuals using data-driven statistical analyses.
METHODS: Cognitive data of 146 EOAD subjects were Z-normalized to 395 cognitively normal (CN) individuals. Domain-averaged Z-scores were adjusted for age, sex, and education followed by Wald cluster analysis of residuals. Magnetic resonance imaging and positron emission tomography comparisons of EOAD clusters to age-matched CN were done using Statistic Parametric Mapping 8. Cluster-level-family-wise error (p < 0.05) correction was applied. Mixed-effect models were used to compute longitudinal change across clusters.
RESULTS: Scree plot using the pseudo-T-squared suggested a 4-cluster solution. Cluster 1 (memory-predominant impairment) showed atrophy/hypometabolism in medial/lateral temporal, lateral parietal, and posterior cingulate regions. Cluster 2 (memory/visuospatial-predominant) showed atrophy/hypometabolism of medial temporal, temporoparietal, and frontal cortices. Cluster 3 (memory, language, and executive function) and Cluster 4 (globally impaired) manifested atrophy and hypometabolism throughout the brain. Longitudinally between-cluster differences in the visuospatial and language/executive domains were significant, suggesting phenotypic variation.
CONCLUSION: We observed significant heterogeneity in cognitive presentation among amnestic EOAD subjects and patterns of atrophy/hypometabolism in each cluster in agreement with the observed cognitive phenotype.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Cognition; Cognitive patterns; Early-onset Alzheimer’s disease; Heterogeneity; Magnetic resonance imaging; Positron emission tomography

Mesh:

Substances:

Year:  2020        PMID: 31901905      PMCID: PMC7031037          DOI: 10.1159/000504341

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  42 in total

1.  Mapping the Progression of Atrophy in Early- and Late-Onset Alzheimer's Disease.

Authors:  Raffaella Migliaccio; Federica Agosta; Katherine L Possin; Elisa Canu; Massimo Filippi; Gil D Rabinovici; Howard J Rosen; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 2.  The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.

Authors:  William J Jagust; Susan M Landau; Robert A Koeppe; Eric M Reiman; Kewei Chen; Chester A Mathis; Julie C Price; Norman L Foster; Angela Y Wang
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

3.  Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline.

Authors:  D Jacobs; M Sano; K Marder; K Bell; F Bylsma; G Lafleche; M Albert; J Brandt; Y Stern
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

4.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

5.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.

Authors:  Manja Lehmann; Pia M Ghosh; Cindee Madison; Robert Laforce; Chiara Corbetta-Rastelli; Michael W Weiner; Michael D Greicius; William W Seeley; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2013-01-28       Impact factor: 13.501

6.  Early-onset Alzheimer's disease: clinical predictors of institutionalization and death.

Authors:  A Heyman; W E Wilkinson; B J Hurwitz; M J Helms; C S Haynes; C M Utley; L P Gwyther
Journal:  Neurology       Date:  1987-06       Impact factor: 9.910

7.  Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: A CERAD analysis, Part XII.

Authors:  E Koss; S Edland; G Fillenbaum; R Mohs; C Clark; D Galasko; J C Morris
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

8.  Factors associated with duration of survival in Alzheimer's disease.

Authors:  L L Barclay; A Zemcov; J P Blass; F H McDowell
Journal:  Biol Psychiatry       Date:  1985-01       Impact factor: 13.382

9.  Should EOAD patients be included in clinical trials?

Authors:  Kinga Szigeti; Rachelle S Doody
Journal:  Alzheimers Res Ther       Date:  2011-02-08       Impact factor: 6.982

10.  The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI).

Authors:  Shannon L Risacher; Sungeun Kim; Li Shen; Kwangsik Nho; Tatiana Foroud; Robert C Green; Ronald C Petersen; Clifford R Jack; Paul S Aisen; Robert A Koeppe; William J Jagust; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Andrew J Saykin
Journal:  Front Aging Neurosci       Date:  2013-04-01       Impact factor: 5.750

View more
  3 in total

Review 1.  Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease.

Authors:  Rachel F Buckley
Journal:  Neurotherapeutics       Date:  2021-03-29       Impact factor: 7.620

Review 2.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

Review 3.  Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.

Authors:  Ranjan Duara; Warren Barker
Journal:  Neurotherapeutics       Date:  2022-01-27       Impact factor: 6.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.